Taken together, these results suggest that dysregulated Rho GTPase–LIMKs-cofilin pathway contributes to the spine, synaptic, and memory deficits of AD and, therefore, targeting this pathway may provide a therapeutic strategy to preserve synaptic function and cognition in AD patients [149,161,162]. Here, CFL1 is linked to Alzheimer disease.